NasdaqGM:OCULPharmaceuticals
Ocular Therapeutix (OCUL) Stock Faces Axpaxli Hopes Against Deepening Losses
Ocular Therapeutix stock inched up about 3% to US$8.40 after earnings, a modest move for a biotech that has been drifting lower over the past quarter. The headline is not about a sudden swing into profit. It is about how much revenue growth investors are willing to pay for when the losses remain heavy.
Quarterly revenue sat in the low teens in millions of US dollars, while net loss stayed deep in the tens of millions. That mix keeps the spotlight on the long term. For anyone looking at Ocular...